Xenoscience Inc.

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Source

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy1 recruiting
• Multiple sclerosis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Phase 3· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Source